Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs.
Infection of porcine alveolar macrophages by the porcine reproductive and respiratory syndrome virus (PRRSV) was significantly enhanced in vitro by antibody raised against the PRRSV isolate ISU-P (p < 0.01). Increased yields and infection rates were highly correlated (r = 0.95) and the ratio of yield to infection rate was greater than 1.4, suggesting that more than one mechanism was responsible for enhanced infection. Antibody-dependent enhancement (ADE) of infection was also demonstrated in vivo using a completely randomized block design (n = 16). The mean level and duration of viremia were greater (p < 0.05) in pigs injected with subneutralizing amounts of PRRSV-specific IgG prior to virus challenge than in control pigs injected with normal IgG. In contrast, virus replication was significantly (p < 0.01) inhibited in pigs with neutralizing antibody titers of 4 log2. The period of time that subneutralizing levels of antibody can persist and contribute to ADE of PRRSV infection was estimated in 4 pigs injected with PRRSV-specific IgG to yield an initial neutralizing antibody titer of 3.8 log2. Neutralizing activity declined to undetectable levels by day 37 postinjection (PI). ADE activity was first detected in undiluted sera on day 20 PI and persisted through day 62 PI. Western immunoblot analysis of sera collected between days 37 and 62 PI detected antibodies specific for the 15-kDa nucleocapsid and 26-kDa glycosylated envelope proteins. These results strongly suggest that ADE has the potential to contribute to the pathogenesis of PRRSV infection and is mediated by antibody specific for the 26-kDa envelope protein.
Yoon
K J
KJ
Veterinary Diagnostic Laboratory, College of Veterinary Medicine, Iowa State University, Ames 50011, USA.
Wu
L L
LL
Zimmerman
J J
JJ
Hill
H T
HT
Platt
K B
KB
D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D018018:Arterivirus / Q000187:drug effects / Q000254:growth & development / Q000276:immunology*; D018174:Arterivirus Infections / Q000276:immunology / Q000662:veterinary* / Q000821:virology; D002478:Cells, Cultured; D016676:Macrophages, Alveolar / Q000166:cytology / Q000276:immunology; D009500:Neutralization Tests; D013205:Staphylococcal Protein A / Q000494:pharmacology; D013552:Swine; D013553:Swine Diseases / Q000276:immunology / Q000821:virology*; D014766:Viremia / Q000276:immunology / Q000662:veterinary
D000914:Antibodies, Viral; D013205:Staphylococcal Protein A